Viridian Therapeutics, Inc./DE Gain (Loss) on Contract Termination
Viridian Therapeutics, Inc./DE (VRDN) reported Gain (Loss) on Contract Termination of -$46.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-21.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnContractTermination · last filed 2016-03-21
- Viridian Therapeutics, Inc./DE gain (loss) on contract termination for fiscal 2014 was -$46.00K.
| Period end | Gain (Loss) on Contract Termination 6 month | Gain (Loss) on Contract Termination 6 month as first filed | Gain (Loss) on Contract Termination 9 month | Gain (Loss) on Contract Termination 9 month as first filed | Gain (Loss) on Contract Termination 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | -$46.00K 10-K · filed 2016-03-21 | ||||
| 2014-09-30 | -$46.00K 10-Q · filed 2015-11-13 | -$45.72K 10-Q · filed 2014-11-14 | |||
| 2014-06-30 | -$46.00K 10-Q · filed 2015-08-14 | -$45.72K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |